HRTX

Over the past six months, Heron Therapeutics' stock has experienced several notable events. The company reported Q4 2025 net revenue of $154.9 million and Q3 2025 net revenue of $38.2 million. Q1 2026 financial results are scheduled to be reported on May 11, 2026. The stock has seen a general decline of 42.86% from May 8, 2025, to May 7, 2026, but has shown recent uptrends. Heron Therapeutics adopted a Section 382 Rights Plan to protect its net operating loss carryforwards. A settlement with Mylan related to CINVANTI and APONVIE patent litigations was announced. Changes in beneficial ownership by an insider or major shareholder contributed to an upbeat sentiment.